Highlights From NCCN

On October 26, 2011, lung cancer screening guidelines were published by the National Comprehensive Cancer Network (NCCN).

The National Comprehensive Cancer Network^® (NCCN^®) is a nonprofit alliance of 21 of the world’s leading cancer centers.

In March, the National Comprehensive Cancer Network (NCCN) guidelines for genetic/familial high-risk assessment for breast and ovarian cancers were updated. Among the updates is a section on “gene panels.”

The National Comprehensive Cancer Network (NCCN) provides clinical practice guidelines in oncology for all types and stages of cancer as well as areas of supportive care.

The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy.

The population of patients with multiple myeloma (MM) who are eligible for therapy has been expanded to asymptomatic patients with certain features under the most recent National Comprehensive Cancer Network (NCCN) guideline (Version 3.2016).

Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), according to the most recent guideline on management of NSCLC issued by the National Comprehensive Cancer Network (NCCN).

The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.

Updated NCCN Breast Cancer Guidelines

The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.

The delivery and receipt of cancer care in value-based healthcare models was the subject of a roundtable discussion at the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference.

Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding.

The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.

Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of pancreatic cancer.

More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).

Hereditary breast and ovarian cancer syndrome and Lynch syndrome (HBOC/LS) are the 2 most common inherited cancer predisposition syndromes.

The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.

Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.